Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold Roche/Biogen Idec, 8 Mar 2010 Accessed on 7 Dec 2011 from http://www.roche.com/media/media_releases/med-cor-2010-03-08.htm. CommentRecommendBookmarkWatch
